Connect your AI

Veradermics MANE Gain (loss) on available-for-sale debt securities

Gain (loss) on available-for-sale debt securities at other companies

Flywire CorporationFLYW

-$34K+73.6%

ImmunomeIMNM

$0+100%

Vera TherapeuticsVERA

-$942K-461%

Grand Canyon EducationLOPE

-$696K-9,843%

First Financial BanksharesFFIN

$0—

ZymeworksZYME

$95K-62.5%

Other financials

Income statement

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

Market cap$4.9B+296%

Returns & leverage

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's gain (loss) on available-for-sale debt securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veradermics 's gain (loss) on available-for-sale debt securities?: Veradermics (MANE) reported gain (loss) on available-for-sale debt securities of -$584K in Q1 2026.
What does gain (loss) on available-for-sale debt securities mean?: This represents the change in the fair value of available-for-sale debt securities that has not yet been realized through a sale. It reflects market fluctuations in the company's investment portfolio. It is a non-cash adjustment to the cash flow statement.